Erlotinib Hydrochloride

ICER is modelled base case; trial-based preliminary analysis ranged $75,000–$105,000 to >$200,000 with considerable uncertainty. PBAC noted these ratios would be even higher if quality-adjusted.

The PBAC also noted that the modelled ICER was sensitive to the time horizon and health care resources. These cost-effectiveness ratios were considered high and uncertain and would be even higher if quality adjusted. PBAC · 2006

PopulationAdults with locally advanced or metastatic non-small cell lung cancer who have previously received chemotherapy, with WHO performance status of 3 or less.

• equi-effectiveness with docetaxel not demonstrated, uncertain cost-effectiveness versus best supportive care, high and uncertain ICERs, lack of conclusive evidence for EGFR-status-based targeting, survival advantage for docetaxel could not be excluded in indirect comparison